Log In Sign up
The largest database of trusted experimental protocols

Cobas ampliprep cobas taqman hiv 1 assay version 2.0

Manufactured by Roche
Visit Supplier
Sourced in United States

The COBAS AmpliPrep/COBAS TaqMan HIV-1 Assay (version 2.0) is an in vitro nucleic acid amplification test for the quantitation of Human Immunodeficiency Virus Type 1 (HIV-1) RNA in human plasma. The assay utilizes automated sample preparation and real-time PCR technology to detect and quantify HIV-1 viral load.

Automatically generated - may contain errors

Lab products found in correlation

Cobas hiv 1 quantitative nucleic acid test cobas 6800, by Roche (5 mentions)

Close spelling variants of this product

Cobas TaqMan (73 citations) COBAS AmpliPrep/COBAS TaqMan (63 citations) COBAS AmpliPrep (41 citations) COBAS TaqMan assay (36 citations) COBAS AmpliPrep/COBAS TaqMan assay (13 citations) TaqMan assay (11 citations) COBAS AmpliPrep/TaqMan (7 citations) Cobas Taqman HIV-1 assay (3 citations)

10 protocols using cobas ampliprep cobas taqman hiv 1 assay version 2.0

1

Quantifying Plasma HIV-1 RNA Levels

Check if the same lab product or an alternative is used in the 5 most similar protocols
Plasma HIV-1 RNA levels were determined at every study visit, including the screening (day −49 to −7) and pre-infusion (day −42 to −2) visits, as well as before the first infusion on day 0 and two days after each infusion. Following the last infusion, HIV-1 RNA levels were monitored weekly for four weeks, and continued to be monitored in two- to eight-week intervals until the end of study follow up. HIV-1 RNA levels were determined using the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Assay (version 2.0) or the Roche cobas HIV-1 quantitative nucleic acid test (cobas 6800). These assays have a linear range of quantitation between 2 × 101 and 1 × 107 viral copies/ml and were performed at LabCorp or at the University Hospital Cologne.
Bar-On Y., Gruell H., Schoofs T., Pai J.A., Nogueira L., Butler A.L., Millard K., Lehmann C., Suárez I., Oliveira T.Y., Karagounis T., Cohen Y.Z., Wyen C., Scholten S., Handl L., Belblidia S., Dizon J.P., Vehreschild J.J., Witmer-Pack M., Shimeliovich I., Jain K., Fiddike K., Seaton K.E., Yates N.L., Horowitz J., Gulick R.M., Pfeifer N., Tomaras G.D., Seaman M.S., Fätkenheuer G., Caskey M., Klein F, & Nussenzweig M.C. (2018). Safety and anti-viral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nature medicine, 24(11), 1701-1707.
+ Open protocol
+ Expand
2

Monitoring Plasma HIV-1 RNA Levels

Check if the same lab product or an alternative is used in the 5 most similar protocols
Plasma HIV-1 RNA levels were determined at every study visit, including the screening (day -49 to -7) and pre-infusion (day -42 to -2) visits, as well as before the first infusion on day 0 and two days after each infusion. Following the last infusion, HIV-1 RNA levels were monitored weekly for four weeks, and continued to be monitored in two- to eight-week intervals until the end of study follow up. HIV-1 RNA levels were determined using the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Assay (version 2.0) or the Roche cobas HIV-1 quantitative nucleic acid test (cobas 6800). These assays have a linear range of quantitation between 2 × 101 and 1 × 107 viral copies/ml and were performed at LabCorp or at the University Hospital Cologne.
Bar-On Y., Gruell H., Schoofs T., Pai J.A., Nogueira L., Butler A.L., Millard K., Lehmann C., Suárez I., Oliveira T.Y., Karagounis T., Cohen Y.Z., Wyen C., Scholten S., Handl L., Belblidia S., Dizon J.P., Vehreschild J.J., Witmer-Pack M., Shimeliovich I., Jain K., Fiddike K., Seaton K.E., Yates N.L., Horowitz J., Gulick R.M., Pfeifer N., Tomaras G.D., Seaman M.S., Fätkenheuer G., Caskey M., Klein F, & Nussenzweig M.C. (2018). Safety and anti-viral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nature medicine, 24(11), 1701-1707.
+ Open protocol
+ Expand
3

Quantifying HIV-1 RNA Levels During Analytic Treatment Interruption

Check if the same lab product or an alternative is used in the 5 most similar protocols
HIV-1 RNA levels in plasma were measured at the time of screening, at week -2, day 0 (before infusion), weekly during ATI, and every two weeks to every eight weeks after viral rebound had occurred. HIV-1 RNA levels were determined using the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Assay (version 2.0) or the Roche cobas HIV-1 quantitative nucleic acid test (cobas 6800), which quantitate HIV-1 RNA over a range of 2x101 to 1×107 copies/ml. These assays were performed at LabCorp or at the University Hospital Cologne.
Mendoza P., Gruell H., Nogueira L., Pai J.A., Butler A.L., Millard K., Lehmann C., Suárez I., Oliveira T.Y., Lorenzi J.C., Cohen Y.Z., Wyen C., Kümmerle T., Karagounis T., Lu C.L., Handl L., Unson-O’Brien C., Patel R., Ruping C., Schlotz M., Witmer-Pack M., Shimeliovich I., Kremer G., Thomas E., Seaton K.E., Horowitz J., West AP J.r., Bjorkman P.J., Tomaras G.D., Gulick R.M., Pfeifer N., Fätkenheuer G., Seaman M.S., Klein F., Caskey M, & Nussenzweig M.C. (2018). Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature, 561(7724), 479-484.
+ Open protocol
+ Expand
4

Measuring HIV-1 RNA Levels Over Time

Check if the same lab product or an alternative is used in the 5 most similar protocols
HIV-1 RNA levels in plasma were measured at the time of screening (within 49 days before the first infusion), day 0 (before infusion), and weekly until week 12, then at weeks 14, 24 and 36. Participants that remained virologically suppressed to <20 c.p.m. off ART beyond week 12, returned for weekly measurements of plasma HIV-1 RNA levels. HIV-1 RNA levels were determined using the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Assay, Version 2.0, which detects between 20 and 1 × 107 c.p.m. This assay was performed at LabCorp.
Scheid J.F., Horwitz J.A., Bar-On Y., Kreider E.F., Lu C.L., Lorenzi J.C., Feldmann A., Braunschweig M., Nogueira L., Oliveira T., Shimeliovich I., Patel R., Burke L., Cohen Y.Z., Hadrigan S., Settler A., Witmer-Pack M., West AP J.r., Juelg B., Keler T., Hawthorne T., Zingman B., Gulick R.M., Pfeifer N., Learn G.H., Seaman M.S., Bjorkman P.J., Klein F., Schlesinger S.J., Walker B.D., Hahn B.H., Nussenzweig M.C, & Caskey M. (2016). HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature, 535(7613), 556-560.
+ Open protocol
+ Expand
5

Quantifying HIV-1 RNA Levels During ATI

Check if the same lab product or an alternative is used in the 5 most similar protocols
HIV-1 RNA levels in plasma were measured at the time of screening, at week −2, day 0 (before infusion), weekly during ATI, and every two weeks to every eight weeks after viral rebound had occurred. HIV-1 RNA levels were determined using the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Assay (version 2.0) or the Roche cobas HIV-1 quantitative nucleic acid test (cobas 6800), which quantitate HIV-1 RNA over a range of 2×101 to 1×107 copies/ml. These assays were performed at LabCorp or at the University Hospital Cologne.
Mendoza P., Gruell H., Nogueira L., Pai J.A., Butler A.L., Millard K., Lehmann C., Suárez I., Oliveira T.Y., Lorenzi J.C., Cohen Y.Z., Wyen C., Kümmerle T., Karagounis T., Lu C.L., Handl L., Unson-O’Brien C., Patel R., Ruping C., Schlotz M., Witmer-Pack M., Shimeliovich I., Kremer G., Thomas E., Seaton K.E., Horowitz J., West AP J.r., Bjorkman P.J., Tomaras G.D., Gulick R.M., Pfeifer N., Fätkenheuer G., Seaman M.S., Klein F., Caskey M, & Nussenzweig M.C. (2018). Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature, 561(7724), 479-484.
+ Open protocol
+ Expand
6

Quantifying HIV-1 RNA Levels

Check if the same lab product or an alternative is used in the 5 most similar protocols
HIV-1 RNA levels in plasma were measured at the time of screening, at week −2, day 0 (before infusion), weekly during ATI, and every two weeks to every eight weeks after viral rebound had occurred. HIV-1 RNA levels were determined using the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Assay (version 2.0) or the Roche cobas HIV-1 quantitative nucleic acid test (cobas 6800), which quantitate HIV-1 RNA over a range of 2 × 101 to 1 × 107 copies per ml. These assays were performed at LabCorp or at the local laboratory at Massachusetts General Hospital.
Gaebler C., Nogueira L., Stoffel E., Oliveira T.Y., Breton G., Millard K.G., Turroja M., Butler A., Ramos V., Seaman M.S., Reeves J.D., Petroupoulos C.J., Shimeliovich I., Gazumyan A., Jiang C.S., Jilg N., Scheid J.F., Gandhi R., Walker B.D., Sneller M.C., Fauci A., Chun T.W., Caskey M, & Nussenzweig M.C. (2022). Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature, 606(7913), 368-374.
+ Open protocol
+ Expand
7

Longitudinal HIV-1 RNA Quantification

Check if the same lab product or an alternative is used in the 5 most similar protocols
Plasma was collected for measuring HIV-1 RNA levels at screening (from d −49 to d −7), the pre-infusion visit (from d -42 to d -1), day 0 (before infusion), and on days 1, 2, 4, 7, 14, 21, 28, 42, 56, 84, 112, 140 and 168. HIV-1 RNA levels were determined using the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Assay, Version 2.0, or the Roche Cobas 6800 HIV-1 kit, which detect 20–10×106 copies/ml.
Caskey M., Schoofs T., Gruell H., Settler A., Karagounis T., Kreider E.F., Murrell B., Pfeifer N., Nogueira L., Oliveira T.Y., Learn G.H., Cohen Y.Z., Lehmann C., Gillor D., Shimeliovich I., Unson-O’Brien C., Weiland D., Robles A., Kümmerle T., Wyen C., Levin R., Witmer-Pack M., Eren K., Ignacio C., Kiss S., West AP J.r., Mouquet H., Zingman B.S., Gulick R.M., Keler T., Bjorkman P.J., Seaman M.S., Hahn B.H., Fätkenheuer G., Schlesinger S.J., Nussenzweig M.C, & Klein F. (2017). Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nature medicine, 23(2), 185-191.
+ Open protocol
+ Expand
8

Measuring Residual HIV Viremia

Check if the same lab product or an alternative is used in the 5 most similar protocols
Plasma HIV-1 RNA was quantified using the Cobas AmpliPrep/CobasTaqMan HIV-1 assay version 2.0 (Roche Diagnostics; lower detection limit of 20 copies/mL). Below this cutoff, the assay indicates the qualitative detection of pHIV-1 RNA in the range of 1 to 20 copies/mL. Residual viremia was measured at baseline and W96: USVL was between 1 and 20 copies/mL when a signal was detected and below 1 copy/mL when there was no detected signal. The measure of USVL was centralized for each trial.
Lambert-Niclot S., Grude M., Meynard J.L., Marcelin A.G., Valantin M.A., Flandre P., Izopet J., Moinot L., Bouteloup V., Calvez V., Katlama C., Girard P.M, & Morand-Joubert L. (2018). Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 67(12).
+ Open protocol
+ Expand
9

CSF HIV-1 RNA Quantification

Check if the same lab product or an alternative is used in the 5 most similar protocols
CSF HIV-1 RNA was measured with COBAS® Ampliprep/COBAS® Taqman® version 2.0 HIV-1 assay (Roche Molecular Systems, Inc, Branchburg, NJ, USA); this assay detects 20 to 10,000,000 copies/mL, with 98.3% sensitivity and 99.4% specificity.
Lahiri C.D., Reed-Walker K., Sheth A.N., Acosta E.P., Vunnava A, & Ofotokun I. (2015). Cerebrospinal Fluid Concentrations of Tenofovir and Emtricitabine in the Setting of HIV-1 Protease Inhibitor-Based Regimens. Journal of clinical pharmacology, 56(4), 492-496.
+ Open protocol
+ Expand
10

Quantifying HIV-1 RNA in Plasma and CSF

Check if the same lab product or an alternative is used in the 5 most similar protocols
Plasma and CSF HIV-1 RNA were measured using the COBAS® Ampliprep/COBAS® Taqman® version 2.0 HIV-1 assay (Roche Molecular Systems, Inc., Pleasanton, CA)26 (link) which detects 20–10,000,000 copies/mL in plasma, with a sensitivity of 98.3% and specificity of 99.4%. Commercial reverse transcriptase PCR assays have been shown to successfully quantitate HIV-1 RNA in other biological compartments, including CSF.27 (link) Because dilution of samples was performed to achieve proper volume necessary for HIV-1 RNA quantification, the lower limit of detection for CSF and plasma samples in this study was 40 copies/mL.
Delille C.A., Pruett S.T., Marconi V.C., Lennox J.L., Armstrong W.S., Arrendale R.F., Sheth A.N., Easley K.A., Acosta E.P., Vunnava A, & Ofotokun I. (2014). Effect of Protein Binding on Unbound Atazanavir and Darunavir Cerebrospinal Fluid Concentrations. Journal of clinical pharmacology, 54(9), 1063-1071.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!